CC
ACAD icon

Centiva Capital’s Acadia Pharmaceuticals ACAD Stock Holding History

Centiva Capital’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-38,200
Closed -$815K – 1270
2025
Q3 		$815K Buy
+38,200
New +$903K 0.01% 535

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Centiva Capital's ACAD Position: Q2 2023 in Review

Centiva Capital sold out of Acadia Pharmaceuticals (ACAD) in Q2 2023, closing a stake of 19,150 shares — an estimated $360K sold.

Centiva Capital first reported a position in ACAD in Q2 2020 and held it in 5 quarters. The position peaked at $1.75M in Q1 2021. 236 funds tracked by Wall St. Rank hold ACAD as of Q2 2023.

  • Centiva Capital reported no remaining Acadia Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Centiva Capital sold 19,150 Acadia Pharmaceuticals shares in Q2 2023, an estimated $360K.
  • Centiva Capital first reported a position in Acadia Pharmaceuticals in Q2 2020 and held it in 5 quarters.
  • Centiva Capital's Acadia Pharmaceuticals position peaked at $1.75M in Q1 2021.
  • 236 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2023.

Based on Centiva Capital's 13F filing for Q2 2023, filed 14 Aug 2023.